IgG4-Related Disease: Navigating Diagnosis and the Expanding B-Cell-Targeted Treatment Landscape - Episode 14
B-Cell Inhibition in IgG4-RD: Phase 3 Trial Design and Outcomes
A first-in-class agent inhibits B cells without depleting them. The panel reviews its mechanism and the largest randomized trial yet conducted in IgG4-related disease.
In "B-Cell Inhibition in IgG4-RD: Phase 3 Trial Design and Outcomes," the panel turns to a reversible approach to B-cell targeting.
Dr. Culver introduces INDIGO, a large phase 3 study of the B-cell inhibitor obexelimab. Dr. Della Torre explains why clinicians were curious about this first-of-its-kind molecule. Rather than killing B cells, it inhibits them. One arm of the molecule docks on CD19, which virtually all B lymphocytes express, simply to select those cells. Another portion binds FcγRIIb, the only inhibitory Fc receptor on B cells. That binding delivers signals that suppress, rather than eliminate, the cells.
In vitro, he notes, obexelimab reduces antibody production, B-cell activation, and antigen presentation to T cells. It also reduces cytokine production. The goal is to inhibit B cells while allowing their function to recover when needed.
Dr. Della Torre calls INDIGO the largest trial ever conducted in IgG4-related disease, involving many centers worldwide. It enrolled 194 patients, randomized to subcutaneous obexelimab or placebo. The design resembled MITIGATE. Patients first achieved remission with glucocorticoids because the trial aimed to assess flare prevention. Outcomes included flare risk, time to flare, remission at 1 year, and cumulative glucocorticoid use.
The major design difference, he explains, was mandatory whole-body imaging at 52 weeks with CT, MRI, or PET. This likely captured asymptomatic relapses that clinicians usually miss without frequent imaging. It may also explain part of the results. The trial met all primary and secondary outcomes. It reduced flare risk by 59%, lowered cumulative glucocorticoid dose, and increased remission rates compared with placebo. During the 52-week randomized period, no major safety signals emerged with obexelimab compared with placebo.
Dr. Culver highlights the subcutaneous route, the inclusion of patients with single-organ involvement, and the use of serial imaging. She also notes the positive primary and secondary results and the favorable tolerability and safety compared with placebo.
Our next episode, "Positioning B-Cell Depletion and B-Cell Inhibition in IgG4-RD Care," features Dr. Katz on where B-cell inhibition may fit alongside depletion and why it could reshape maintenance therapy.
